The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial

Lise J Estcourt, Zoe McQuilten, Gillian Powter, Claire Dyer, Eleanor Curnow, Erica M Wood, Simon J Stanworth, TREATT Trial Collaboration (provisional), Lise J Estcourt, Zoe McQuilten, Gillian Powter, Claire Dyer, Eleanor Curnow, Erica M Wood, Simon J Stanworth, TREATT Trial Collaboration (provisional)

Abstract

Background: Patients with haematological malignancies often develop thrombocytopenia as a consequence of either their disease or its treatment. Platelet transfusions are commonly given to raise a low platelet count and reduce the risk of clinical bleeding (prophylaxis) or stop active bleeding (therapy). Recent studies have shown that many patients continue to experience bleeding despite the use of prophylactic platelet transfusions. Tranexamic acid is an anti-fibrinolytic, which reduces the breakdown of clots formed in response to bleeding. Anti-fibrinolytics have been shown to prevent bleeding, decrease blood loss and use of red cell transfusions in elective and emergency surgery, and are used widely in these settings. The aim of this trial is to test whether giving tranexamic acid to patients receiving treatment for haematological malignancies reduces the risk of bleeding or death and the need for platelet transfusions.

Methods: This is a multinational randomised, double-blind, placebo-controlled, parallel, superiority trial. Patients will be randomly assigned to receive tranexamic acid (given intravenously or orally) or a matching placebo in a 1:1 ratio, stratified by site. Patients with haematological malignancies receiving intensive chemotherapy or stem cell transplantation (or both) who are at least 18 years of age and expected to become severely thrombocytopenic for at least 5 days will be eligible for this trial. The primary outcome of the trial is the proportion of patients who died or had bleeding of World Health Organization grade 2 or above during the first 30 days of the trial. We will measure the rates of bleeding daily by using a short, structured assessment of bleeding, and we will record the number of transfusions given to patients. We will assess the risk of arterial and venous thrombosis for 120 days from the start of trial treatment.

Discussion: This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders.

Trial registration: This study was prospectively registered on Current Controlled Trials on 25 March 2015 (ISRCTN73545489) and is also registered on ClinicalTrials.gov (NCT03136445).

Keywords: Anti-fibrinolytic; Bleeding; Chemotherapy; Haematological malignancy; Haematopoietic stem cell transplant; Leukaemia; Lymphoma; Thrombocytopenia; Tranexamic acid.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Trial schema
Fig. 2
Fig. 2
Assessment of adverse events/reactions

References

    1. Cameron B, Rock G, Olberg B, et al. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion. 2007;47:206–211. doi: 10.1111/j.1537-2995.2007.01090.x.
    1. Eikenboom JC, van Wordragen R, Brand A. Compliance with prophylactic platelet transfusion trigger in haematological patients. Transfus Med. 2005;15:45–48. doi: 10.1111/j.1365-3148.2005.00547.x.
    1. Estcourt L, Birchall J, Lowe D, et al. National Comparative Audit of Platelet Transfusions in Haematology Patients. BBTS Annual Meeting. Glasgow: Transfusion Medicine; 2011. p. S106.
    1. Greeno E, McCullough J, Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion. 2007;47:201–205. doi: 10.1111/j.1537-2995.2007.01089.x.
    1. Qureshi H, Lowe D, Dobson P, et al. National comparative audit of the use of platelet transfusions in the UK. Transfus Clin Biol. 2007;14:509–513. doi: 10.1016/j.tracli.2008.01.002.
    1. Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev. 2010;24:163–171. doi: 10.1016/j.tmrv.2009.11.002.
    1. Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol. 2011;154:425–440. doi: 10.1111/j.1365-2141.2010.08483.x.
    1. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–613. doi: 10.1056/NEJMoa0904084.
    1. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. N Engl J Med. 2013;368:1771–1780. doi: 10.1056/NEJMoa1212772.
    1. Heddle N, Webert K. Investigation of acute transfusion reactions. In: Murphy M, Pamphilion D, editors. Practical Transfusion Medicine. 3rd ed: Blackwell; 2009. p. 63–89.
    1. Popovsky M, Moore S. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573–577. doi: 10.1046/j.1537-2995.1985.25686071434.x.
    1. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106–4114. doi: 10.1182/blood-2003-08-2724.
    1. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med. 1997;337:1870–1875. doi: 10.1056/NEJM199712253372602.
    1. Stanworth Simon J., Estcourt Lise J., Llewelyn Charlotte A., Murphy Michael F., Wood Erica M. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial (CME) Transfusion. 2014;54(10):2385–2393. doi: 10.1111/trf.12646.
    1. PHB Bolton-Maggs (Ed), D Poles, et al. The 2014 Annual SHOT Report. 2015.
    1. NHS Blood and Transplant. Price List for Blood and Components 2013/2014 [Available from: .
    1. Pendry K, Davies T. An audit of the use and wastage in the North West of England and North Wales - where have all the platelets gone? Blood Transfus Matters. 2011;34:17–19.
    1. Okamoto S, Hijikata-Okunomiya A, Wanaka K, et al. Enzyme-controlling medicines: introduction. Semin Thromb Hemost. 1997;23:493–501. doi: 10.1055/s-2007-996127.
    1. Roberts I. Tranexamic acid in trauma: how should we use it? J Thromb Haemost. 2015;13(Suppl 1):S195–S199. doi: 10.1111/jth.12878.
    1. Ker K, Edwards P, Perel P, et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. doi: 10.1136/bmj.e3054bmj.
    1. Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 2013;100:1271–1279. doi: 10.1002/bjs.9193.
    1. Hibbs SP, Roberts I, Shakur-Still H, et al. Post-partum haemorrhage and tranexamic acid: a global issue. Br J Haematol. 2018;180:799–807. doi: 10.1111/bjh.15073.
    1. Estcourt LJ, Desborough M, Brunskill SJ, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database Syst Rev. 2016;3:CD009733. doi: 10.1002/14651858.CD009733.pub3.
    1. Avvisati G, ten Cate JW, Buller HR, et al. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;2:122–124. doi: 10.1016/S0140-6736(89)90181-5.
    1. Shpilberg O, Blumenthal R, Sofer O, et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk Lymphoma. 1995;19:141–144. doi: 10.3109/10428199509059668.
    1. NCT02578901 . American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) 2015.
    1. NCT02650791. Platelet Transfusion Requirements in Hematopoietic Transplantation (PATH). ClinicalTrialsgov 2016.
    1. Collett D. Modelling survival data in medical research. Florida: Chapman & Hall/CRC; 2003.
    1. Dyer C., Alquist C. R., Cole-Sinclair M., Curnow E., Dunbar N. M., Estcourt L. J., Kaufman R., Kutner J. M., McCullough J., McQuilten Z., Potiphar L., Rioux-Masse B., Slichter S., Tinmouth A., Webert K., Yokoyama A. P., Stanworth S. J. A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy. Vox Sanguinis. 2018;113(3):251–259. doi: 10.1111/vox.12627.
    1. Estcourt LJ, Heddle N, Kaufman R, et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion. 2013;53:1531–1543. doi: 10.1111/trf.12058.
    1. Cella D, Beaumont J, Webster K, et al. Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy–Thrombocytopenia (FACT-Th) questionnaire. Support Care Cancer. 2006;14:1220–1231. doi: 10.1007/s00520-006-0102-1.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren